Approval · Notice of Compliance 30937 · 2023

DILANTIN: Notice of Compliance 30937

Issued June 7, 2023

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 30937
Date: June 7, 2023
Company: BGP Pharma ULCEtobicoke, Ontario, Canada
Product type: Prescription Pharmaceutical
Submission: New Drug Submission (NDS)
Submission class: Admin
Reason: Administrative: Change in Product Ownership

Products in this notice

Brand	DIN	Status today
DILANTIN	00022772	Marketed
DILANTIN	00022780	Marketed

Medicinal ingredients

PHENYTOIN SODIUM 30 MG per CAP
PHENYTOIN SODIUM 100 MG per CAP